Pharmacists in Dubai are perceiving themselves chemists n and pharmacologists

Pharmacists in Dubai are perceiving themselves chemists (48.5%, n=96) and pharmacologists (35.4%, n=70) so that healthcare professionals concerned with dispensing medicines ignoring the important management part as only 14.1% (n=28) of the respondents perceived themselves managers and 13.1% (n=26) saw that they have some sales responsibilities. The findings of this study are analogous with similar study where how to do molarity pharmacists used the word ‘dispensing’ or dispensing-related terms to describe their professional role (Rosenthal et al., 2011).
The new trend of community pharmacists in Dubai is providing extra pharmacy services. According to this study, community pharmacists provide services like educating patients on the use of nutritional supplements (67.7%, n=134), suitable diet plans (58.6%, n=116), skin care (49.5%, n=98), herbal medicines (48.5%, n=96), and weight reduction methods (48.5%, n=96). Similar findings were gathered from a study that was done in rural community pharmacies in Western Australia where patients were more keen to ask pharmacists questions related to issues above and over the traditional dispensing role of pharmacists (Wibowo et al., 2010).
The decision to choose one particular pharmacy by patients depends on many factors such as pharmacy location, friendly staff, fast and quality service, and appearance of a pharmacy (Merks et al., 2014). Similar outcomes were shown in the neighbor state ‘Qatar’, where the location of a pharmacy, provision of a good range of products and services, convenient pharmacy opening hours, and pharmacist’s professional knowledge were considered primary choice factors (El Hajj et al., 2011). These findings were persistent with results extracted from this study. Pharmacists in Dubai were found keen in taking care of their patients in a good way to ensure retaining them for long time (Table 6).

Study limitations

Conclusion

Disclaimer

Funding Information

Ethical Approval

Introduction
With a steady increase in the prevalence of diabetes from 1980 to 2011, it is estimated that by the year 2030, 552 million people will have diabetes (Whiting et al., 2011), thus the great burden will be brought worldwide by the huge increase in type 1 and 2 diabetes population, of which type 2 diabetes people account for about 90–95% of all diagnosed cases of diabetes (Gavin et al., 2010; Nyenwe et al., 2011). Although current therapies for type 2 diabetes include lifestyle modification of diet and exercise as first-line therapy, pharmacotherapy is considered an essential component for effective glycemic control (Nathan, 2009). Glucagon-like peptide-1 (GLP-1) receptor agonists are a novel class of pharmacotherapies that provide effective glycemic control with low risk of hypoglycemia and weight loss (Drucker, 2007; Sebokova et al., 2010a). Taspoglutide is a long-acting human GLP-1 analogue and considered to have equivalent potency to natural GLP-1 (Nauck et al., 2009). This GLP-1 analogue has been shown to elicit a long-lasting incretin effect, and sustained glycemic control (Raz et al., 2012).
Taspoglutide contains aminoisobutyric acid which is covalently attached to the GLP-1 sequence at positions 8 and 35 of the native GLP-1 peptide (Dong et al., 2011). These structure modifications prolong the half-life of the circulating complex without otherwise changing its biological activity. Also, apparently, the aminoisobutyric acid molecule sterically inhibits DPP-4 enzyme from degrading taspoglutide (Sebokova et al., 2010b). Taspoglutide shows high binding affinity to the human GLP-1 receptor (Pratley et al., 2013) and its biological activity is not affected through assessment of its relative activity on cyclic adenosine monophosphate stimulation (Sebokova et al., 2010b). Its resistance to DPP-4 enzyme degradation and a zinc-based sustained release formulation confer an extended half-life and allow for QW subcutaneous administration (Ratner et al., 2010). Several multiple dosing regimens in clinical trials have showed that taspoglutide 10 or 20mg compared with placebo to patients with type 2 diabetes reduced FPG levels, stimulated insulin secretion and reduced glucagon levels with weight loss (Nauck et al., 2009; Bergenstal et al., 2012; Henry et al., 2012; Raz et al., 2012).